Phase II randomized, placebo-controlled trial of M. vaccae-derived protein (PVAC) for the treatment of psoriasis

Vaccine
Eduardo Martins NettoRoberto Badaro

Abstract

The treatment effect against psoriasis of an antigen (delipidated, deglycolipidated form of M. vaccae-PVAC) was investigated. One hundred and sixty-five patients were enrolled in three arms (50 or 15 microg or placebo), each receiving a total of two intradermal injections (days 0 and 21). At week 12, a 75% decrease in psoriasis area and severity index was similar among the studied groups (13, 9 and 18%, p=0.429). The overall incidence of adverse events was significantly higher in the PVAC treated groups when compared to placebo (98.2, 87.3 and 70.9%; p<0.001) largely due to local reactions that were limited for the most part to grades 1 and 2 in severity and were self-limiting. Despite its overall safety, PVAC was not clearly indicated to be superior to placebo in the treatment of psoriasis in this study.

References

Jul 10, 1998·FEMS Immunology and Medical Microbiology·A LehrerJ Stanford
Mar 19, 1999·Immunology Today·J D Bos, M A De Rie
Aug 25, 1999·Journal of the American Academy of Dermatology·S R RappD M Reboussin
Sep 10, 2002·European Journal of Vascular and Endovascular Surgery : the Official Journal of the European Society for Vascular Surgery·N C AbbotJ L Stanford
Aug 2, 2003·Journal of the American Academy of Dermatology·M Alan MenterGerald D Weinstein
Aug 2, 2003·Journal of the American Academy of Dermatology·Jane Choi, John Y M Koo
Aug 2, 2003·Journal of the American Academy of Dermatology·Steven R Feldman
Aug 2, 2003·Journal of the American Academy of Dermatology·Mark Lebwohl
Feb 24, 2004·Frontiers in Bioscience : a Journal and Virtual Library·John StanfordJohn Grange
Feb 27, 2004·Journal of Tropical Pediatrics·Maria de Fatima P Militão de AlbuquerqueVamberto Maia Filho
Jun 8, 2004·Current Drug Targets. Inflammation and Allergy·Khusru AsadullahWolfram Sterry
Feb 15, 2005·Annals of the Rheumatic Diseases·R G B LangleyC E M Griffiths
Jun 14, 2005·The British Journal of Dermatology·J D BosG Piskin
Jan 3, 2006·The Journal of Allergy and Clinical Immunology·Johan VerhagenCezmi A Akdis

❮ Previous
Next ❯

Citations

Mar 19, 2009·Archives of Dermatological Research·Jose Antonio O'DalyJ Gleason
Nov 17, 2010·Indian Journal of Dermatology, Venereology and Leprology·Amrinder J KanwarSunil Dogra
Feb 5, 2014·Human Vaccines & Immunotherapeutics·Benjamin H KaffenbergerHenry K Wong

❮ Previous
Next ❯

Related Concepts

Related Feeds

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.